Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 5, 2014, Pages 889-896

  Cadnapaphornchai, Melissa A ^a   George, Diana M ^a   McFann, Kim ^a   Wang, Wei ^a   Gitomer, Berenice ^a   Strain, John D ^b   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMLODIPINE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CHORIONIC GONADOTROPIN; CREATINE KINASE; CREATININE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ABDOMINAL MAGNETIC RESONANCE; ADULT; AGE; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; COUNSELING; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FATTY LIVER; FEMALE; FOLLOW UP; GENDER; HEART LEFT VENTRICLE MASS; HEMATOCRIT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMAGING; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; MICROALBUMINURIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PREGNANCY; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; TOTAL KIDNEY VOLUME; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; ALBUMINURIA; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; HEART VENTRICLE; KIDNEY; ORGAN SIZE; PATHOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; URINE;

ADOLESCENT; ALBUMINURIA; CHILD; CREATININE; DOUBLE-BLIND METHOD; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MAGNETIC RESONANCE IMAGING; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PRAVASTATIN; YOUNG ADULT;

EID: 84904573694     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08350813     Document Type: Article

References (48)

1. Somlo S, Chapman AB: Autosomal dominant polycystic kidney disease. In: Schrier’s Diseases of the Kidney, edited by Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, 9th Ed., Philadelphia, Lippincott Williams & Wilkins, 2012, pp 519–563
2. MacDermot KD, Saggar-Malik AK, Economides DL, Jeffery S: Prenatal diagnosis of autosomal dominant polycystic kidney disease (PKD1) presenting in utero and prognosis for very early onset disease. J Med Genet 35: 13–16, 1998
3. Pretorius DH, Lee ME, Manco-Johnson ML, Weingast GR, Sedman AB, Gabow PA: Diagnosis of autosomal dominant polycystic kidney disease in utero and in the young infant. J Ultrasound Med 6: 249–255, 1987
4. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4: 820–829, 2009
5. Hafez KS, Inman SR, Stowe NT, Novick AC: Renalhemodynamic effects of lovastatin in a renal ablation model. Urology 48: 862–867, 1996
6. Glazer AA, Inman SR, Stowe NT, Novick AC: Renal microcir-culatory effects of lovastatin in a rat model of reduced renal mass. Urology 50: 812–817, 1997
7. Inman SR, Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Satoh S, Satodate R, Vidt DG: Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317: 215–221, 1999
8. Joyce M, Kelly C, Winter D, Chen G, Leahy A, Bouchier-Hayes D: Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion. J Surg Res 101: 79–84, 2001
9. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565–570, 2003
10. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16: 2152–2157, 2001
11. Stowe NT, Inman SR, Tapolyai M, Brouhard BH, Hodge EE, Novick AC: Lovastatin has direct renal hemodynamic effects in a rodent model. J Urol 156: 249–252, 1996
12. McFarlane SI, Muniyappa R, Francisco R, Sowers JR: Clinical review 145: Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 87: 1451–1458, 2002
13. Gile RD, Cowley BD, Gattone VH, O’Donnell MP, Swan SK, Grantham JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26: 501–507, 1995
14. Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL: Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. AmJPhysiol Renal Physiol 293: F854–F859, 2007
15. Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD, Schrier RW: Effect of statin therapy on disease progression in pediatric ADPKD: Design and baseline characteristics of participants. Contemp Clin Trials 32: 437–445, 2011
16. Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58: 259–263, 1976
17. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20: 629–637, 2009
18. Marshall WA, Tanner JM: Growth and physiological development during adolescence. Annu Rev Med 19: 283–300, 1968
19. Marshall WA, Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child 44: 291–303, 1969
20. Marshall WA, Tanner JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child 45: 13–23, 1970
21. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114[Suppl 4th Report]: 555–576, 2004
22. Artigao LM, Llavador JJ, Puras A, Lόpez Abril J, Rubio MM, Torres C, Vidal A, Sanchis C, Divisόn JA, Naharro F, Caldevilla D, Fuentes G:[Evaluation andvalidationofOmron Hem 705CPand Hem 706/711 monitors for self-measurement of blood pressure]. Aten Primaria 25: 96–102, 2000
23. O’Brien E, Waeber B, Parati G, Staessen J, Myers MG: Blood pressure measuring devices: Recommendations of the European Society of Hypertension. BMJ 322: 531–536, 2001
24. Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW: Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6: 369–376, 2011
25. Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, Kenney PJ, King BF, Glockner JF, Wetzel LH, Brummer ME, O’Neill WC, Robbin ML, Bennett WM, Klahr S, Hirschman GH, Kimmel PL, Thompson PA, Miller JP; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radio-logic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64: 1035–1045, 2003
26. Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW; HALT PKD Study Group: Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int 81: 577–585, 2012
27. Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, Li J, King BF, Martin D, Wetzel LH, Lockhart ME, Harris PC, Moxey-Mims M, Flessner M, Bennett WM, Grantham JJ: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. ClinJ AmSoc Nephrol7:479–486, 2012
28. O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126–1131, 1997
29. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–1135, 1998
30. Laufs U: Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58: 719–731, 2003
31. Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder TE: Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43: 854–860, 2004
32. Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW: Increased left ventricular mass in children with au- tosomal dominant polycystic kidney disease and borderline hy pertension. Kidney Int 74: 1192–1196, 2008
33. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, Matsuo K, Saku K: Statins induce the regression of left ventricular mass in patients with angina. Circ J 68: 121–125, 2004
34. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW: Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am J Kidney Dis 39: 1127–1134, 2002
35. Fencl F, Janda J, Bláhová K, Hríbal Z, Stekrová J, Puchmajerová A, Seeman T: Genotype-phenotype correlation in children with autosomal dominant polycystic kidney disease. Pediatr Nephrol 24: 983–989, 2009
36. Winterfeld U, Allignol A, Panchaud A, Rothuizen LE, Merlob P, Cuppers-Maarschalkerweerd B, Vial T, Stephens S, Clementi M, De Santis M, Pistelli A, Berlin M, Eleftheriou G, Maňáková E, Buclin T: Pregnancy outcome following maternal exposure to statins: A multicentre prospective study. BJOG 120: 463–471, 2013
37. Costantine MM, Cleary K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric–Fetal Pharmacology Research Units Network: Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 121: 349–353, 2013
38. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD: Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: A systematic review. Hypertension 60: 444–450, 2012
39. Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G: Ter-atogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 31: 465–472, 2011
40. Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A: Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Re-prod Toxicol 31: 540–545, 2011
41. Kostapanos MS, Liberopoulos EN, Elisaf MS: Statin pleiotropy against renal injury. J Cardiometab Syndr 4: E4–E9, 2009
42. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO: Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. FASEB J 20: 1706–1708, 2006
43. Reed BY, Masoumi A, Elhassan E, McFann K, Cadnapaphornchai MA, Maahs DM, Snell-Bergeon JK, Schrier RW: Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int 79: 128–134, 2011
44. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G: Improvement of left ventricular remodeling and function by hy-droxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982–985, 2001
45. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X: Simvastatin inhibits cardiac hypertrophyand angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 26: 903–908, 1999
46. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystickidney disease. JAm Soc Nephrol8: 1292–1297, 1997
47. Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Bae KT, Meyers CM; HALT PKD Study Group: Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 2508–2515, 2011
48. Chapman AB, Johnson AM, Gabow PA, Schrier RW: Overt pro-teinuria and microalbuminuria in autosomal dominant poly-cystic kidney disease. J Am Soc Nephrol 5: 1349–1354, 1994